Amicus Therapeutics Reports Preliminary 2024 Revenue and Provides 2025 Strategic Outlook
Provided By GlobeNewswire
Last update: Jan 12, 2025
2024 Total Revenue of $528M, Representing Significant Growth of 32% Year-Over-Year1
Strong and Growing Demand for Galafold® and Pombiliti® + Opfolda®
Read more at globenewswire.com
